Drugs / EBV gp350-Ferritin
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06908096 | May 2025 → Oct 2027 expected | infectious mononucleosis | National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05683834 | Sep 2023 → Apr 2026 | infectious mononucleosis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EBV gp350-ferritin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06908096 ↗ |
| Modality | Vaccine | “To test two EBV vaccines: EBV gH/gL/gp42-ferritin and EBV gp350-ferritin.” NCT06908096 ↗ |
| Route | Intramuscular | “The gp350-Ferritin vaccine will be delivered intramuscularly into the deltoid muscle at Days 0, 30, and between 60 and 90.” NCT05683834 ↗ |